Results 111 to 120 of about 803,874 (212)
The Contribution of Blood Serum Biomarkers to the Prediction of Cognitive Decline by fMRI and Apolipoprotein-E in Healthy Older Adults [PDF]
Biomarkers are a promising approach to the prediction and early intervention of Alzheimer\u27s disease. We demonstrated that cortical functional MRI (fMRI) activation during a semantic memory task and apolipoprotein-E ?4 allele inheritance (APOE?4 ...
Nielson, Kristy A. +6 more
core +1 more source
Nonalcoholic fatty liver disease (NAFLD) encompasses a broad range of conditions, commencing with simple steatosis and progressing to non‐alcoholic steatohepatitis, with the possibility of further deterioration into fibrosis, cirrhosis, and ultimately ...
Yuhe Jiang +9 more
doaj +1 more source
Localization of apolipoprotein A-I and apolipoprotein A-II in human atherosclerotic arteries.
Apolipoprotein A-I and apolipoprotein A-II, the two major protein components of the high-density lipoproteins, were visualized in human arteries using an immunofluorescence technique. Apolipoprotein A-I and apolipoprotein A-II were codeposited into the intima and upper media of normal arteries of atherosclerotic patients.
P, Bedossa +5 more
openaire +1 more source
Neural Dedifferentiation in Relation to Risk for Alzheimer\u27s Disease [PDF]
Functional magnetic resonance imaging (fMRI) research indicates that as an individual\u27s age increases, the task-related spatial extent of neural activation increases.
Hantke, Nathan C.
core +1 more source
Episodic Memory Measures Complement Structural and Functional MRI for Predicting Cognitive Decline in Apolipoprotein E ε4 Carriers [PDF]
Apolipo-protein E (APOE) ?4 allele carriers demonstrate greater risk for cognitive decline and Alzheimer\u27s disease than non-carriers. However, factors associated with risk of decline among APOE ?4 carriers are not well-known.
Butts, Alissa +11 more
core +1 more source
Serum apolipoprotein A-II and alpha-2-antiplasmin levels in midtrimester can be used as predictors of preterm delivery. [PDF]
Huang J, Yang Y, He P.
europepmc +1 more source
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. [PDF]
Wolska A +20 more
europepmc +1 more source

